
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is positioned to be a leader in the gene therapy space, with a strong focus on ophthalmology and cardiology therapies. Their gene therapy asset 4D-150 has shown potential in treating wet age-related macular edema and diabetic macular edema and is expected to reach commercial success with its convenient route of administration and promising safety profile. Despite competition from other emerging therapies, 4D has a solid plan for commercialization and a well-rounded pipeline with potential for future growth in the cystic fibrosis gene therapy market. With their recent positive clinical trial results and plans for upcoming phase II and III trials, 4D is positioned for success in the gene therapy industry.
Bears say
4D Molecular Therapeutics is a developmental biotechnology company focusing on gene therapies for multiple therapeutic areas, including ophthalmology, cardiology, and pulmonology. Despite the company's promising product candidates and delivery technology, there are several risks that may impact its success, including the need for additional financing before achieving profitability and the uncertainty of regulatory approval for gene therapy products. These risks could lead to a downward revision of the company's target price.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares